Abstract 177P
Background
Stomach cancer (SC) ranks as the 3rd leading cause of death among all cancer-related fatalities in the South Asia (SA) region. The complex interplay of cultural, lifestyle, and demographic factors in SA compounds the challenge to public health posed by the significant burden of stomach cancer.
Methods
Using the Global Burden of Disease framework, this study examined deaths and disability-adjusted life years (DALYs) attributed to SC caused by smoking by age, sex, and year across the 5 countries of the SA region from 1990-2019. Additionally, projections for the number of deaths up to 2040 were derived through regression analysis.
Results
The total count of deaths attributed to SC due to smoking witnessed an increase from 6,948 (95%UI: 4,963-8,890) in 1990 to 9,353 (95%UI: 6,632-12,325) in 2019. Concurrently, DALYs rose from 177,675 (95%UI: 124,165-232,327) in 1990 to 222,290 (95%UI: 149,831-299,787) in 2019. Assessing the annual percentage of change (APC), the Age-Standardized Mortality Rate (ASMR) experienced a decline of 49% from 1990-2019. Among the SA countries, Nepal exhibited the highest APC increase in total deaths at 76%, followed by Bhutan at 73%, India at 40%, Pakistan at 20%, and Bangladesh at 13% from 1990-2019. Conversely, the APC increase in DALYs was greatest in Nepal at 51%, while Bangladesh reported the lowest increase at 3% during the same period. Notably, the age group of 65-69 years recorded the highest number of deaths (1,555), while the age group of 60-64 years experienced the highest DALYs (37,194) in 2019. In terms of gender disparities, males bore a higher burden of stomach cancer attributable to smoking compared to females over the past three decades. The study's projections indicate an estimated 3,952 deaths (95%UI: 2,036-6,347) by the year 2040.
Conclusions
While notable advancements have been made in the management of SC, the burden attributed to smoking continues to rise over the last 3 decades. This accounts for 9.44% of deaths among the overall causes of SC-related fatalities. It emphasizes the importance of comprehensive tobacco control strategies to mitigate this burden, considering the diverse social, economic, and cultural factors unique to the region.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
184P - Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)
Presenter: Yuki Sonoda
Session: Poster Display
Resources:
Abstract
185P - Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
186P - Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial
Presenter: Xiaoting Ma
Session: Poster Display
Resources:
Abstract
187P - Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
Presenter: Yongguang Wei
Session: Poster Display
Resources:
Abstract
188P - Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Margherita Rimini
Session: Poster Display
Resources:
Abstract
189P - Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Shun Yamamoto
Session: Poster Display
Resources:
Abstract
190P - Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
Presenter: Jiaxing He
Session: Poster Display
Resources:
Abstract
191P - Predictive value of CXCR6 expression in gastric cancer survival and immune modulation
Presenter: Song-Hee han
Session: Poster Display
Resources:
Abstract
192P - Antiangiogenesis-related adverse events (ARAE) to predict efficacy in patients with advanced gastric cancer (AGC) treated with apatinib + chemotherapy: Results from two prospective studies
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
193P - Impact of coronavirus disease 2019 on patients with unresectable hepatocellular carcinoma treated with atezolizumab/bevacizumab
Presenter: Hongjae Chon
Session: Poster Display
Resources:
Abstract